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Abstract 
 Huntington’s disease is an incurable, progressive neurological disorder 
characterized by loss of motor control, psychiatric dysfunction, and eventual dystonia 
leading to death.  Despite the fact that this disorder is caused by a mutation in one 
single gene, there is no cure.  The mutant Huntingtin (mHtt) protein is expressed 
ubiquitously throughout the brain but frank cell death is limited to the striatum.  Recent 
work has suggested that Rhes, Ras homolog enriched in striatum, which is selectively 
expressed in the striatum, may play a role in Huntington’s disease neuropathology.  In 
vitro studies have shown Rhes to be an E3 ligase for the post-translational modification 
protein SUMO.  Rhes increases binding of SUMO to mHtt which competes for the same 
binding site as Ubiquitin.  SUMOylation of mHtt leads to disaggregation and cellular 
death, whereas ubiquitination leads to aggregation and cellular protection.  In a previous 
study we showed that deletion of Rhes caused a decrease in the Huntington’s disease 
phenotype in mice.  We hypothesized that mice lacking Rhes would also show 
increased aggregation in the striatum and this increased aggregation would correlate in 
a rescue of behavioral symptoms.  Despite the prior in vitro and in vivo evidence, 
deletion of Rhes in vivo did not alter the aggregation of mHtt in the striatum of mice 
however deletion of Rhes still showed a rescue from the diseased phenotype.   This 
result would indicate that deletion of Rhes alters the neurobehavioral phenotype of 
Huntington’s disease through a different pathway than promoting aggregation in striatal 
cells.     
Keywords: Rhes, RasD2, Huntington’s Disease, Huntingtin, mHtt, aggregate   
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Introduction 
Background 
George Huntington first characterized a novel disease in a landmark paper in 
which he described a 1xpression disorder with a specific genetic inheritance, manifest in 
mid-adulthood, and leading to insanity (1872).  This far predated modern molecular 
genetics and we now know that Huntington’s disease (HD) is an autosomal dominant 
disorder due to an unstable expansion of the trinucleotide repeat CAG coding for the 
amino acid glutamine located at 4p16.3 (Huntingtons Disease Collaborative Research 
Group, 1993).  The CAG repeat is naturally occurring at a low frequency; however the 
threshold for showing symptoms in humans is in the range of 36-41 repeats (Andrew et 
al., 1993; Kremer et al., 1994; Rubinsztein et al., 1996).  Studies have also shown that 
the length of the repeats is negatively correlated to the onset age of symptoms such 
that the disease is anticipated early (Duyao et al., 1993).  The mean age of onset in HD 
is difficult to predict but typically is in middle age between 30 and 50 years of age 
(Langbehn, Brinkman, Falush, Paulsen, & Hayden, 2004) with a range of onset from 5 
years of age to 85 years of age (Andrew et al., 1993; S. Chen, Ferrone, & Wetzel, 
2002). 
HD differentially affects the neurons of the striatum (Dunlap, 1927 ; Vonsattel et 
al., 1985), despite the fact that the allele is expressed ubiquitously throughout the body 
(Sharp et al., 1995).  HD leads to eventual cell death as evidenced by studies showing 
severely decreased volume of basal ganglia structures (de la Monte, Vonsattel, & 
Richardson, 1988; Vonsattel et al., 1985).  The cell death is further restricted to the 
medium spiny neurons (Sapp et al., 2004; Saudou, Finkbeiner, Devys, & Greenberg, 
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1998) which make up to 95% of the dorsal striatum (Graybiel, Ragsdale, & Edley, 
1979), and especially that of the enkephalin and D2-receptor expressing medium spiny 
neurons (Saudou et al., 1998).     
The exact cause of the cell death in HD has not been elucidated, but several 
factors have been identified that contribute to the process, including aggregation of 
mutant Huntingtin (mHtt) protein forming intranuclear inclusions (DiFiglia et al., 1997), 
impaired dopamine signaling (Filloux et al., 1990), decrease in Brain-Derived 
Neurotrophic Factor (BDNF) transcription (Zuccato et al., 2001), and oxidative stress 
leading to mitochondrial dysfunction (Browne, Ferrante, & Beal, 1999; Goswami et al., 
2006; Polidori, Mecocci, Browne, Senin, & Beal, 1999).  Reviewing the literature, it is 
evident that these processes are not mutually exclusive adding to the complexity of the 
disease process especially since they precede frank cell death.   
The progression of the disease usually begins with the onset of either 
neurocognitive symptoms and/or psychological changes that precede actual motor 
dysfunction.  Studies have shown early changes in visuospatial functioning, working 
memory, and set shifting, sometimes several years in advance of motor dysfunction 
(Foroud et al., 2004; Jason et al., 1988; Rupp et al., 2010).  Numerous studies have 
also shown changes in psychological dimensions such as anxiety, depression, and loss 
of motivation (Craufurd, Thompson, & Snowden, 2001; Duff, Paulsen, Beglinger, 
Langbehn, & Stout, 2007; Thompson, Snowden, Craufurd, & Neary, 2002), which often 
give way to full blown psychosis (Rosenbaum, 1940) and often lead to suicide 
(Huntington, 1872; Shoenfeld et al., 1984).  
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Although the psychiatric and cognitive features of HD are very important, the 
hallmark symptoms for which the diagnosis is made involves motor disturbances.  The 
main motor disturbances of HD are chorea, or involuntary movements, as well as 
dystonia, or rigidity of muscles.  Generally the symptoms are due to loss of motor 
control beginning slowly with the inability to control minor movement, however; this 
leads to chorea which manifests as inability to control movement of the eyes, face, 
limbs, and trunk as well as erratic facial and occulomotor control, problems with ataxia 
and gate, and twisting or jerking of the limbs (Conneally, 1984; Huntington, 1872; 
Sturrock & Leavitt, 2010).  Dystonia is the inability to move voluntarily and this is 
characteristic of patients with juvenile onset of HD (Vonsattel & DiFiglia, 1998), as well 
as in patients with advanced HD that had previously displayed 3xpression movements 
(Sturrock & Leavitt, 2010).  Aspiration pneumonia is the number one cause of death in 
HD due to eventual loss of the ability to control swallow and esophageal tone (Sorenson 
& Fenger, 1992).  
Huntington’s Disease as a Public Health Concern  
 Given its severe symptomology and prolonged time course, HD exacts a massive 
toll on the healthcare apparatus.  Because the disease is incurable, the treatment 
options are limited.  Treatment plans mostly focus on the management of symptoms 
through pharmacotherapy.  According to two separate meta analysis of 2,620 subjects 
from 30 separate trials receiving various pharmacological treatments, only one drug, 
tetrabenazine, was shown to be effective in management of chorea (Mestre, Ferreira, 
Coelho, Rosa, & Sampaio, 2009a, 2009b).  Given the ineffectiveness of 
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pharmacological treatment, managing the progression of the disease in such a manner 
as to provide for quality of life becomes the clear goal.   
Costs 
Utilization and costs are very difficult to estimate in HD.  Prodromal 
symptomology may go on for years and require treatment well before the patient is 
diagnosed with the disease.  Another problem with estimating utilization and costs are 
detangling the direct costs of the disease from seemingly unrelated or peripheral 
treatments, and the problem of trying to estimate the long term care costs, especially 
when such care is provided at home and utilizes paid but unskilled workers.  Family 
involvement may also indirectly account for costs in the form of lost productivity as a 
family member is pulled away from work and increasingly into the home to take care of 
the affected individual.  One European study of 451 HD patients shows a large majority 
of patients utilizing both formal and informal healthcare (Busse et al., 2011).   As of 
initial collection of data, the researchers found that 75% of the patients had used or 
were using hospital based services, and 89% were using community or outpatient 
services (Busse et al., 2011).  They also showed a trend for an increase in utilization of 
in home care services (Busse et al., 2011), which is to be expected given the 
progressive nature of the disease.   Even this well executed study does not provide a 
very clear picture of the progressive nature of the disease.  Although utilization of 
services was measured at three time points, many of the participants were in different 
stages of the disease process.  Given this information, inference from this study should 
be restricted to overall utilization, and only represents a limited population as the 
sample was from a registry of patients.  No longitudinal studies could be identified that 
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directly measured patterns of utilization of healthcare services.  Given the nature of the 
disease it is relatively easy to infer that the general course involves years of prodromal 
treatment, most likely in an outpatient setting.  This would be followed by years of more 
intensive outpatient care with simultaneous home health care.  This would again be 
followed by several years of intensive skilled nursing either in a facility or at the home 
eventually giving way to palliative or hospice care. 
 Costs can reflect the amount of services required over the course of the disease.  
One cross sectional study from 2002 estimated the direct costs of one year of treatment 
at an average of $18,000 per patient (Murman et al., 2002).  This study also lacks a 
well-defined approach to control for severity of disease at the time of sampling. It also 
has a low sample number (51) drawn from an Alzheimers disease registry which may 
not represent the population of HD patients (Murman et al., 2002).  The Huntington’s 
Disease Society of America estimates that some 30,000 people in the United States 
suffer from Huntington’s disease and another 250,000 are at risk (Huntington’s Disease 
Society of America, 2011).  An extremely conservative estimate of total direct costs 
based on the average costs from the study previously discussed, adjusting for inflation 
and the estimated number of Americans affected, is $650 million dollars annually.  This 
does not take into account skyrocketing healthcare costs, the number of affected who 
are not identified, and indirect costs such as family loss of productivity.  The Society for 
Neuroscience estimates the societal costs of Huntington’s disease at a staggering $2 
billion dollars annually as of its publication in 2005 (Society for Neuroscience, 2005). 
Given these numbers, and the severity of the disease process, it is a clear public health 
concern that necessitates the need to for basic research.   
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Genetics of Huntington’s Disease 
 The key feature of the huntingtin gene is an area located near the 5’ end of the 
coding segment that is highly polymorphic for a triplet repeat codon of CAG 
(Huntingtons Disease Collaborative Research Group, 1993).   As previously mentioned, 
CAG codes for the amino acid glutamine, and its repeating code results in a stretch of 
glutamine residues also known as a polyglutamine tract (polyQ).  The presence of the 
CAG repeat in the huntingtin gene in humans is ubiquitous (Andrew et al., 1993); 
however there is much variation in the number of repeats occurring in individuals.  One 
of the consistent findings in HD research is that an increase in the number of CAG 
repeats leads to a quicker disease progression and an earlier age of onset (Andrew et 
al., 1993; Brandt et al., 1996; Brinkman, Mezei, Theilmann, Almqvist, & Hayden, 1997; 
Penney, Vonsattel, MacDonald, Gusella, & Myers, 1997; Rosenblatt et al., 2006; 
Ruocco, Bonilha, Lopes-Cendes, & Cendes, 2008).  Age of onset is an important 
discussion due to the clinical implications of the disease.  Understanding the mean age 
of onset and progression of symptoms can help to provide information not only about 
the genetic aspects of the disease but also can help to guide timing with interventions 
that are developed in the future.  
Disease Onset 
 It has been found that the CAG repeat length in the disease accounts for 50% of 
the variation in the age of onset of the disease (Andrew et al., 1993).  Studies have 
identified cases in which individuals with repeats in the lower range, >35 and <42 
repeats, may not ever express pathology during a normal lifetime (Andrew et al., 1993; 
Rubinsztein et al., 1996).  Only one study has identified a case in which Huntington’s 
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disease was contracted with ≤35 repeats in which 1 patient with 30 repeats and two 
patients with 31 repeats were identified (Snell et al., 1993).  This may have been the 
result of very early genotyping of the huntingtin gene resulting in a primer design that 
did not take into account the flanking CCG repeats.  No other cases of HD have been 
reported with a CAG repeat length of ≤35 repeats (Andrew et al., 1993; Kremer et al., 
1994; Langbehn et al., 2004; Rubinsztein et al., 1996).  This evidence suggests that, 
even though HD is highly genetically penetrant, it is not 100% certain that the disease 
will manifest in the lower range of pathological repeats.   
 Most patients will have an onset of Huntington’s disease with a mean age range 
of 30-50 years (Andrew et al., 1993; Langbehn et al., 2004).  Despite this clustering of 
onset around middle age the ranges of actual cases are quite extreme with one case 
exhibiting symptoms as young as 5 years of age (Andrew et al., 1993; S. Chen et al., 
2002) and others not showing symptom onset until they are elderly (Andrew et al., 
1993).  Despite the mean, it is interesting that the juvenile onset cases do not always 
contain more repeats than normal mid-life onset cases (Andrew et al., 1993). Juvenile 
onset cases tend to present with a different phenotype than that of adult onset cases.  
Juvenile onset HD also has a different symptom profile as it is most often marked by 
immediate dystonia and less 7xpression activity as well as a much quicker 
neuropathological degeneration (Vonsattel & DiFiglia, 1998; Vonsattel, Keller, & 
Ramirez, 2011).  One phenomenon that may be responsible for this exaggerated 
phenotype is that striatal tissue specifically induces large amounts of instability in the 
gene, such that there are increased numbers of CAG repeats, in some cases up to a 
thousand (Kennedy et al., 2003). The longer the original repeat, the more likely it is to 
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show large tissue specific instability (Kennedy et al., 2003).  No evidence supports a 
current explanation as to why this might occur, but it may very well explain why juvenile 
cases occur even when the normal DNA sample collected from blood or buccal swab 
reveals a median CAG repeat length.  Also, Kennedy et al. (2003) believe that this 
might also explain why juvenile onset cases present with immediate dystonia and a 
more widespread neuropathogenesis than adult onset cases.  They propose that the 
extremely long CAG repeats in the brain impart a more global neurotoxic effect that 
essentially speeds up the neuropathological process, whereas with median length 
repeats seen in adults, the pathology is more limited to the striatum and temporally 
slower in degeneration (Kennedy et al., 2003).    
 CAG Expansion   
 Several theories of unstable expansion have been posed.  In HD resulting from 
the expansion of intermediate sized CAG repeats (30-35), one of the key features for 
unstable expansion was a loss of two triplet sequences which fall in between the CAGn 
and CCGn repeats (Chong et al., 1997).  The wild-type sequence normally looks like 
(CAG)n CAA CAG CCG CCA (CCG)n, but when the CAA and CCA are changed to 
match the CAG and CCG respectively, the net result is unstable expansion (Chong et 
al., 1997).  Several studies utilizing yeast artificial chromosomes have repeatedly found 
that instability in both CAG and CTG repeats is the result of meiotic recombination 
(Cohen, Sears, Zenvirth, Hieter, & Simchen, 1999; Jankowski & Nag, 2002; Jankowski, 
Nasar, & Nag, 2000; Schweitzer, Reinke, & Livingston, 2001).  Generally, the repeats 
form hairpin structures resulting in breaking of the DNA strand, which in turn results in a 
recombination event in which an expansion occurs (Jankowski et al., 2000).  
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  Another set of studies have found evidence to implicate DNA replication 
slippage in CAG repeat expansion in which replication that occurs on the lagging strand 
leads to improper joining of Okazaki fragments that have formed hairpin structures 
(Freudenreich, Kantrow, & Zakian, 1998; Miret, Pessoa-Brandao, & Lahue, 1998; 
Schweitzer & Livingston, 1998).  Another possibility for increases in length of repeats 
may result from defective repair of damaged DNA in somatic tissue that has generally 
been shown to increase with instability over the age range and can be highly varied 
based on the type of tissue (Fortune, Vassilopoulos, Coolbaugh, Siciliano, & Monckton, 
2000; Kennedy & Shelbourne, 2000; Richard, Goellner, McMurray, & Haber, 2000; 
Telenius et al., 1994).  The idea of differential expression based on tissue type is highly 
important and points to the possibility of epigenetic mechanisms. 
 Studies have also found that there may be a contribution by the chromosome 
regulatory factor transcriptional repressor CTCF.  This regulator of chromatin structure 
and insulation has binding sites that flank the CAG repeats of huntingtin gene (Filippova 
et al., 2001).  Another study has shown that binding of transcriptional factor  CTCF at its 
sites adjacent to CAG repeats provides repeat stability through various methylation 
control abilities, whereas mutant binding sites leads to a much higher rate of CAG 
instability (Libby et al., 2008).  Inability of this epigenetic regulator to properly protect the 
repeat site from instability may be a possible mechanism for differences in transmission 
between males and females.  
Paternal Transmission 
 Many studies of HD have found significant correlations with paternal transmission 
and anticipation such that larger repeats are transmitted via the father to the offspring 
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and earlier ages of onset are expected via epigenetic imprinting (Farrer, Cupples, Kiely, 
Conneally, & Myers, 1992; Kremer et al., 1995; Norremolle, Sorenson, & Hasholt, 1995; 
Ranen et al., 1995; Rooij et al., 1993).  In a study of the expansion of CAG repeats, it 
was found that fathers are much more likely to impart instability to their offspring, with a 
21.9% chance of stability compared to mothers with a 36.3% chance of stability, and a 
much larger 25.2% chance of offspring contracting the CAG repeat (Kremer et al., 
1995).  The most interesting finding of this study is that in parent-child transmission in 
the normal population CAG expansion only happened with paternal transmission 
(Kremer et al., 1995).  One study found that in sperm taken from the general population 
and from those with a family history of sporadic HD, the probability of passing on an 
expanded allele from an intermediate sized allele (30-35 CAG repeats) is two times 
greater in the families prone to sporadic HD (Chong et al., 1997).  This evidence 
suggests that there is some epigenetic imprinting which makes males more prone to 
passing on an expanded repeat than females.  
 All of these ideas add intriguing support to the idea that males impart more 
instability to their offspring.  Spermatogenesis in males is in an ongoing process 
throughout the lifespan, whereas in women, the formation of oocytes is a finite process 
that occurs before birth.  These mechanisms all have a much higher probability of 
producing an expanded repeat due to successive damage in males whereas in females 
the DNA of the oocyte would be temporally unaffected.  Most likely, all of these different 
mechanisms play a part in the potential for the CAG repeat to expand resulting in 
instability passed onto to successive generations.   
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Weakness of Diagnostic Criteria  
 One of the major weaknesses in the human studies on CAG repeat length and 
onset age is the lack of well-defined diagnostic criteria.  Going over the methods of the 
major studies of CAG repeat length it is apparent that diagnostic criteria were not 
necessarily clear.  In Andrew et al. (1993) age of onset was defined as “age at which 
the first clearly defined abnormality was apparent including involuntary movement, 
psychiatric or cognitive abnormalities, or inability to perform complex hand movements 
as defined by clumsiness.” This is a very broad interpretation of age of onset.  Other 
studies use a more refined criteria such as Ranen et al. (1995) who defines age of 
onset as simply “motor disturbance defined as chorea (or, in the absence of chorea, as 
rigidity), and voluntary movement abnormalities.”  Other studies failed to define age of 
onset altogether (Kremer et al., 1995; Rubinsztein et al., 1996).  This lack of well-
defined diagnostic criteria can lead to spurious interpretations of the results of these 
studies.  It is now well accepted that cognitive symptoms often precede actual motor 
dysfunction in HD (Butters, Sax, Montgomery, & Tarlow, 1978; Ho et al., 2003; 
Lawrence et al., 1998).  One approach may require that the genotypes be known prior 
to diagnosis.  In this way it may be more relevant to look for onset of either cognitive or 
motor symptoms to mark onset as confidence in genetic testing is extremely high.  
When genotype cannot be inferred prior to diagnosis (e.g. Andrew et al., 1993) 
choosing a much more rigid diagnostic criteria provides a more useful operational 
definition and results in much better external validity.   
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Cellular Features of Huntington’s Disease 
Role of Huntingtin 
 As with many other genetic disorders, the classification and function of non-
mutant Huntingtin protein (Htt) has largely been overshadowed by the necessity to 
understand the functions of the disease causing mutant Huntingtin (mHtt).  As a result, 
much of what we know about the function of endogenous Htt is the result of the study of 
HD.  However, one of the key questions that remain regarding HD is whether or not the 
pathogenesis of the disease is related to a loss of function of the normally functioning 
protein, or a gain of function of the mutant protein.  For this reason it is important to 
understand the function of the normal protein to put into prospective findings regarding 
the pathogenesis related to the mutant protein. 
   The location of the gene was first found to be on chromosome 4 by a large 
linkage analysis study of individuals affected by HD (Gusella et al., 1983) and 
subsequently spurred the collaboration of a large group of investigators to identify the 
location of the responsible gene.  This group, using a location cloning approach located 
the gene, IT15, at 4p16.3 (Huntingtons Disease Collaborative Research Group, 1993).  
Sequence analysis of the IT15 gene indicated that it was coding for 3,144 amino acids 
resulting in a ≈348kD protein with a highly polymorphic area coding for a poly-L-
glutamine tract (polyQ) starting at the 18th amino acid from the 5’ terminus (Huntingtons 
Disease Collaborative Research Group, 1993).   
 The tertiary structure of Htt has yet to be resolved, but this is not surprising given 
the size of the protein.  Much work has been done to understand the structure of the N-
terminal region containing the polyQ expansion.  X-ray crystallography has shown that 
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exon-1 of Htt resolves to form an alpha helix for the first 20 residues that gives way to a 
irregularly structured loop containing the remainder of the polyQ region that is then 
connected to a polyproline helix (M. W. Kim, Chelliah, Kim, Otwinowski, & 
Bezprozvanny, 2009).  Proline is a special amino acid in that its side chain forms a loop 
with an unchanging dihedral angle of 60o making it the most conformationally restricted 
amino acid (Voet, Voet, & Pratt, 2008).   This is interesting because it has been found 
that in expanded polyQ regions present in mHtt, the secondary structure resolves to a 
beta sheet conformation (Poirier, Jiang, & Ross, 2005).  In fact one study has shown 
that manipulation of the number of prolines following a given number of glutamines can 
induce either a polyproline helix or beta sheet structure (Darnell, Orgel, Pahl, & 
Meredith, 2007).  This work suggests that the polyproline tract that follows the polyQ 
region is responsible for preserving the polyQ secondary structure via steric hindrance.  
Evidence of this was also found by Scherzinger et al. (1997) who produced GST-
huntingtin fusion proteins containing different polyQ expansions.  Investigation of the 
cleavage products showed that insoluble aggregates were found for polyQ stretches 
containing 51 repeats or more, and further that the solubility of smaller products would 
have been increased by the GST tag suggesting that even smaller mHtt fragments can 
become insoluble (Scherzinger et al., 1997).  Ultrastructural analysis of these insoluble 
products showed amyloid like plaques highly consistent with a β-sheet structure 
(Scherzinger et al., 1997).  This is important as the difference between not having HD 
and having the full blown disease is simply 1 additional glutamine molecule from 35 to 
36 as was discussed in the section regarding CAG repeats.   
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 The exact function of normal Htt has not yet been identified, but several studies 
have provided evidence pointing to some potential functions of the protein.  Certainly Htt 
is necessary for proper neurogensis.  Mice with a null mutation for the Huntington 
disease homolog (Hdh) gene are not viable and show an increase in apoptotic cell 
death in the ectoderm during differentiation and show abnormalities in development of 
the basal ganglia (Nasir et al., 1995; Zeitlin, Liu, Chapman, Papaioannou, & Efstratiadis, 
1995).  This is further supported by the fact that several knock-in and transgenic mouse 
models of HD are quite viable showing no gross anatomical abnormalities between 
unaffected controls (Duyao et al., 1995; Fortune et al., 2000; Gray et al., 2008 ; 
Hodgson et al., 1999; Mangiarini et al., 1996; Wheeler et al., 2002; Yamamoto, Lucas, & 
Hen, 2000).  Mice heterozygous for a null mutation at the Hdh allele interestingly 
showed an increase in locomotor activity in an open field but a sharp decrease in time 
spent swimming in the platform quadrant of the Morris water maze suggesting an 
increase in locomotion and decrease in cognition (Nasir et al., 1995).   Another study 
using a conditional knockout technique found that when Hdh was inactivated in mature 
mice they displayed deficits in locomotion, increased clasping, tremor, hypoactivity, and 
a decrease in lifespan of nearly half when compared with mutant controls (cre/loxp 
null/null) (Dragatsis, Levine, & Zeitlin, 2000).  Taken together these findings certainly 
lead to the conclusion that Htt plays a crucial role in neurodevelopment as well as 
proper motor functioning and cognition. 
 Evidence regarding the cellular functions of Htt points strongly to a role in the 
regulation of neuronal vesicles.  Htt has been found to be expressed ubiquitously 
throughout the brain (DiFiglia et al., 1995; Gutekunst et al., 1995).  Further investigation 
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revealed that Htt is expressed in the cytosol and is co-precipitated with a number of 
proteins associated with vesicles including SV2, synaptophysin, and the 
15xpression1515 receptor (DiFiglia et al., 1995).  Immunohistochemical analysis 
revealed that Htt is closely associated with vesicle membranes and microtubules 
(DiFiglia et al., 1995; Gutekunst et al., 1995).  Htt has also been shown to be closely 
associated with clatharin (Velier et al., 1998) as well as number of other proteins 
associated with vesicle transport (Block-Galarza et al., 1997), and endocytosis 
(Kalchman et al., 1997).  Although the exact function of Htt has yet to be described, this 
evidence suggests that it does have a role in vesicle regulation and the secretory 
pathways. mHtt aggregates have also shown to be involved in the dysregulation in 
trafficking of both organelles and elements of the secretory system, namely vesicles.  
Ultrastructural analysis has shown that aggregates in neuronal process can immobilize 
mitochondria (Chang, Rintoul, Pandipati, & Reynolds, 2007; Orr et al., 2008), prevent 
dynamin activity by accumulation (Qin et al., 2004), and reduce the movement of 
vesicles in axons (Gunawardena et al., 2003).  This evidence is supported by the fact 
that Htt has been shown to be associated with secretory machinery as previously 
mentioned.  Loss of function of both the normal role of Htt in secretory pathways and 
possibility of gain of aberrant function in the same pathways could result in disruption of 
normal neural transmission.   
Transcriptional Dysregulation  
 One of the contributors to the pathophysiology of HD is undoubtedly the 
dysregulation of transcription that occurs as a result of mHtt.  Transcription is the 
activation of a series of proteins that are responsible for the coding of mRNA from DNA 
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and the subsequent translation of proteins in the cell.  This process is paramount to the 
normal functioning of all other cellular processes.  Essentially it is what determines 
which proteins will be expressed in a cell at any given time along the continuum of the 
organism’s life.  The compliment of proteins present in a cell regulates every cellular 
function.    
 mHtt has been shown to interact with the transcriptional process at many levels.  
Evidence has been found that large groups of mRNAs are downregulated in HD.  
Downregulation of mRNA through investigation by in situ hybridization or microarray has 
been shown for a number of neuropeptides as well as neurotransmitters including brain-
derived neurotrophic factor (BDNF) (Zuccato et al., 2001; Zuccato et al., 2008), 
oxytocin, vasopressin, CART, neuropeptide Y, prepro-thyroid-stimulating hormone-
releasing hormone, prepro-somatostasin, enkephalin (Kotliarova et al., 2005).  
Receptors that have been shown to be downregulated include the BDNF receptor TrkB,  
(Zuccato et al., 2008) D1 and D2 receptors (Augood, Faull, & Emson, 1997; Cha et al., 
1998),  as well as N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-methyl-4-
isoxazolepropionic acid receptors (Giralt et al., 2009).  Ion channels including Ca2+, Na+, 
and K+ have also been shown to have the same pattern of downregulation (Luthi-Carter 
et al., 2000).  The mRNAs for cytoskeletal proteins protocadherin 20, neurobin 1, and 
actinin alpha 2 which are involved in regulation of synapses, synaptic plasticity, synapse 
formation, and dendrite integrity have also been shown to be downregulated (Becanovic 
et al., 2010). Clearly the presence of mHtt causes widespread perturbations in proper 
functioning of neural signaling via a net downregulation in the production of mRNA 
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related to normal neurotransmission at the level of the neurotransmitter, receptor, ion 
channel, and even the structure of the synapse.     
  One of the striking characteristics of this downregulation is the fact that it is not 
necessarily due to downstream regulation caused by inefficient or improperly 
functioning signaling cascades.  mHtt has been shown to act as a regulator of 
transcription factors themselves (Benn et al., 2008; Hu, McCaw, Hebb, Gomez, & 
Denovan-Wright, 2004; Steffan et al., 2000) and in some cases act on the DNA directly 
to alter transcription (Benn et al., 2008; Sadri-Vakili et al., 2007; Steffan et al., 2001).  
Evidence points to several possible mechanisms for the ability of mHtt to interact with 
transcriptional regulation.  One possibility is that aggregated mHtt acts as a molecular 
net to sequester transcription factors in the cytosol thus leading to decreased 
transcription (Huang et al., 1998; Nucifora et al., 2001; Shimohata et al., 2000).  One of 
the properties of the polyQ expansion is the formation of the β-sheet structure as 
described earlier.  This β-sheet conformation allows for a unique interaction between 
strands in the sheet such that hydrogen bonds are formed between them producing 
what has been termed the polar zipper (Perutz, 1995).  This conformation, especially 
when formed into a large regular structure, would have the unique ability to hydrogen 
bond with other proteins that also possess a polyQ region.  This also has the 
consequence of making mHtt fragments complimentary to the promoter regions that are 
bound by these polyQ containing transcription factors thus potentially blocking them or 
activating them inappropriately.    
 However, evidence has also been found that some of the more ubiquitously 
affected transcription factors including cAMP response element-binding protein (CREB) 
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and TATA-binding protein showed no co-immunoreactivity with mHtt aggregates 
suggesting other possible mechanisms (Yu, Li, Nguyen, & Li, 2002).  Another more 
interesting mechanism for the transcriptional dysregulation is the idea that mHtt acts 
directly on DNA.  Studies have found that mHtt can associate directly with DNA 
especially at the level of promoters thus effectively blocking transcription factors (Benn 
et al., 2008; Cui et al., 2006 ; Kegel et al., 2002).   It has also been shown that mHtt 
may act at the level of histones to affect transcription.  Studies have found that mHtt 
acts to block the site of histone acetyltransferases (Igarashi et al., 2003; Steffan et al., 
2000), and also that mHtt increases the presence of monoubiquityl histone 2A which is 
responsible for methylation of histone H3 (M. Kim et al., 2008).  Histones are proteins 
that are integral in the arrangement of DNA such that they function as substrates in 
which genetic material is wrapped around to form chromatin (Cheung, Allis, & Sassone-
Corsi, 2000).  Through modifications such as phosphorylation, acetylation, and 
methylation, histones act to regulate the transcriptional availability of genetic material by 
binding or unbinding it allowing for the availability of promoter regions to be bound by 
transcription factors (Cheung et al., 2000).  By blocking the acetylation (Igarashi et al., 
2003; Steffan et al., 2000) or increasing the methylation (M. Kim et al., 2008) of 
histones, mHtt can cause large areas of DNA to be unavailable to transcription factors 
thus downregulating transcription.  One of the most promising treatments recently under 
review for use in HD is the use of histone deacetyltransferases. These drugs have 
shown a number of benefits in reduction of symptomology both at the behavioral and 
anatomical level in HD models (Bates, Victor, Jones, Shi, & Hart, 2006; Ferrante et al., 
2003 ; Steffan et al., 2001). 
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Brain Derived Neurotrophic Factor 
 The most researched of the transcriptionally dysregulated proteins is that of the 
neuropeptide BDNF.  BDNF is a trophic factor which is critically important in the 
differentiation and survivability of neurons (Barde, Edgar, & Thoenen, 1982; Jones, 
Farinas, Backus, & L.F., 1994; Korsching, 1993) and has been localized in both the 
nigrostriatal and corticostriatal pathways (Hyman et al., 1991; Ivkovic, Polonskaia, & 
Ehrlich, 1997; Yurek, Lu, & Hipkens, 1996 ; Zuccato et al., 2001).  BDNF is produced in 
cortical neurons that project to the striatum providing trophic support and it has been 
shown that Htt upregulates the production of BDNF in cortical neurons projecting into 
the striatum (Zuccato et al., 2001).  Htt has also been shown to be involved in the 
proper trafficking of BDNF containing vesicles along microtubules in cortical neurons 
that project into the striatum (Gauthier et al., 2004).   
 As Htt has been shown to affect regulation of BDNF so has mHtt been shown to 
disrupt regulation of BDNF.  Levels of BDNF transcription are severely downregulated in 
animal models of HD and humans suffering from HD and (Ciammola et al., 2007; 
Ferrer, Goutan, Marin, Rey, & Ribalta, 2000; Zuccato et al., 2001; Zuccato et al., 2005; 
Zuccato et al., 2008).  Post mortem examination of human HD brains has shown that 
there are reduced populations of the TrkB receptor in caudate and an upregulation in 
the low affinity neurotrophin receptors T-Shc and p75NTR suggesting impaired BDNF 
signaling (Zuccato et al., 2008).   
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 Another promising therapeutic intervention is the replacement of BDNF.  Studies 
have found that in models of HD, upregulation of BDNF expression or replacement of 
BDNF through exogenous introduction causes a decrease in loss of striatal neurons, 
improved synaptic function, increased synaptic plasticity, and reversal of the HD 
phenotype (Bemelmans et al., 2004; Cepeda et al., 2004; Duan et al., 2008; Gharami, 
Xie, An, Tonegawa, & Xu, 2008; Kells et al., 2004; Peng et al., 2008; Simmons et al., 
2009; Y. Xie, Hayden, & Xu, 2010)  Interestingly, the selective serotonin reuptake 
inhibitor sertraline has been shown to accomplish this upregulation of BDNF (Duan et 
al., 2008; Peng et al., 2008).  This research on BDNF is exemplary of the fact that 
Huntington’s disease is both the interruption of normal Htt functioning and the gain of 
aberrant functioning of mHtt in that one normal transcript is not enough to overcome the 
gain of aberrant function of mHtt.   
Mitochondrial Dysfunction  
 Mitochondria are organelles located in the cytoplasm that are responsible for 
cellular respiration which produces the main energy source of the organism; adenosine 
triphosphate (ATP).  Mitochondria themselves most likely evolved in eukaryotes as a 
symbiotic prokaryotic organism as they have distinct features of prokaryotic cells 
including a membrane, inner and outer membrane environments, membrane potentials, 
DNA, and the ability to express proteins (McBride, Neuspiel, & Wasiak, 2006).  
Mitochondria not only function to produce the energy currency of the body, ATP, they 
also play a crucial role in intracellular Ca2+ regulation, and are intricately involved in 
intracellular signaling events (McBride et al., 2006; Rizzuto et al., 2009).  The striatum is 
particularly vulnerable to perturbations of mitochondria as several studies have shown 
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that disruptions in mitochondrial function can lead to movement disorders and striatal 
degeneration (Martin et al., 1988; Sarzi et al., 2007; Spruijt et al., 2007).   
 Another important finding in HD research is that mHtt interacts with cellular 
mitochondria causing their dysfunction.  mHtt N-terminal cleavage fragments have been 
shown to associate with the mitochondrial membrane and endoplasmic reticulum (ER) 
(Choo, Johnson, MacDonald, Detloff, & Lesort, 2004; Rockabrand et al., 2007).  
Mitochondria are responsible for the proper storage of Ca2+ and regulate the intracellular 
Ca2+ concentration (McBride et al., 2006), but that has been shown to be disrupted with 
the presence of mHtt (Panov et al., 2002; Rockabrand et al., 2007; Seong et al., 2005).  
mHtt associates with the mitochondrial membrane destabilizing the membrane potential 
across the mitochondria causing poor Ca2+ permeability, and as a result of increased 
NMDA Ca2+ conduction, which is a separate effect of mHtt (Cepeda et al., 2001; Sun, 
Savanenin, Reddy, & Liu, 2001), causes excitotoxic cellular conditions (Gellerich et al., 
2008; Milakovic, Quintanilla, & Johnson, 2006).  A similar consequence of altered 
membrane potential is that it prevents the uptake of adenosine diphosphate (ADP) thus 
directly altering cellular respiration (Seong et al., 2005).  Another mechanism of 
mitochondrial dysfunction is suggested by evidence that 2 subunits of the enzyme 
succinate dehydrogenase, which is critical to cellular respiration, are severely reduced 
in a striatal-specific manner in both humans suffering from HD and in HD models 
(Benchoua et al., 2006).  Eukaryotic cells must contain properly functioning 
mitochondria in order to survive, and this evidence suggests that disruptions of 
mitochondrial function by mHtt may be a cause of neuronal loss in HD.    
Excitotoxicty  
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 Another possible cause for the neural degeneration seen in HD may be due to 
excitotoxicity. Much of the input to the striatum is the result of five parallel circuits that 
connect the frontal cortex to the striatum via glutamatergic efferents (Alexander, 
DeLong, & Strick, 1986; Roberts & Anderson, 1979; Tekin & Cummings, 2002).  Early 
experiments showed that overstimulation of striatum with glutamate or the NMDA 
receptor agonist quinolic acid could indeed cause neurodegeneration (Foster, Collins, & 
Schwarcz, 1983; Mangano & Schwarcz, 1982; McBean & Roberts, 1984).  In fact, 
quinolic acid has been used extensively to model HD in animals due to its ability to 
mimic the striatal neurodegeneration that existed in HD especially before genetic 
models of HD were designed (Beal et al., 1986).   
 As pointed out in the section above on mitochondrial dysfunction, mHtt has 
shown to be responsible for an increase in the magnitude of NMDA receptor-mediated 
calcium influx (Cepeda et al., 2001; Sun et al., 2001).  Part of this increase in calcium 
conductance has been linked to an upregulation in the expression of the NR2B subunit 
of the NMDA receptor (Arzberger, Krampfl, Leimgruber, & Weindl, 1997; Li et al., 2003).  
Cells with an over-expression of the NR2B subtype of the NMDA receptor show much 
larger evoked potentials in cells expressing mHtt (N. Chen et al., 1999).  In models of 
HD, it has also been shown that cells expressing larger numbers of NR2B type NMDA 
receptors show larger NMDA receptor-mediated currents than wild type animals 
(Shehadeh et al., 2006; Zeron et al., 2002).   Studies in which intervention to down-
regulate the expression of the NR2B subunit type of NMDA receptor or block it with 
NR2B antagonist prevents cell loss (Shehadeh et al., 2006; Zeron et al., 2002).  This 
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net gain in calcium influx, along with calcium dysregulation by mitochondria, provides a 
sound hypothetical means for cellular death.   
 
 
 
 
Aggregates 
 One of the earliest reported neuropathological findings in HD other than 
degeneration of the striatum was the presence of nuclear membrane indentations in 
striatal neurons observed through electron-microscopical ultrastructural analysis 
techniques (Bots & Bruyn, 1981; Roizin, Stellar, & Liu, 1979).  It wasn’t until 18 years 
later that the first studies found the cause of the indentations.   
 Not long after the discovery of the sequence for the huntingtin gene, researchers 
began trying to localize the Htt protein in the brain using immunohistochemical methods.  
In 1995, Marian DiFiglia and colleagues developed the first set of polyclonal antibodies 
to Htt.  They generated, in rabbits, antibodies raised to amino acid sequence regions of 
the Htt protein at residues 1-17, 585-745, and 2911-3140 resulting in purified antibodies 
Ab1, Ab585, and Ab2911 respectively (DiFiglia et al., 1995).  All three antibodies 
showed highly specific labeling for Htt as verified by SDS-PAGE and western blot 
analysis which confirmed specificity for a protein of 320kD (DiFiglia et al., 1995).  
Immunohistochemical techniques showed that Htt was expressed ubiquitously 
throughout the brain of both humans and rats (DiFiglia et al., 1995).  Both ultrastructural 
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analysis as well as fractionation techniques revealed proximity of Htt in patches of the 
cytoplasm, membranes of vesicles, golgi, microtubules associated with vesicles, in the 
cell body, dendrites, axons, and axon terminals (DiFiglia et al., 1995).   At the very same 
time another group of researchers were carrying out a nearly identical experiment.  
Sharp et al. (1995) raised polyclonal antibodies to the N-terminal region as well as to an 
internal area of the Htt protein from residues 650-663.  Using the exact same 
methodology as DiFiglia et al. (1995), they were able to draw the same conclusions 
regarding the expression of Htt as well as its intracellular localization (Sharp et al., 
1995).  This was an important discovery.  It showed that Htt is expressed throughout the 
brain which raised the ever more important question of why gross degeneration was 
largely confined to the striatum in HD. 
 Not long after this study was published a group of researchers, using a 
monoclonal antibody raised against 38 Q residues in the TATA-binding protein, was 
able to show specific binding to mHtt using western blot analysis (Trottier et al., 1995).  
However the mAB1c2 antibody bound polyQ stretches in other proteins rather 
indiscriminately, and because it was raised against a longer stretch of polyQ, had very 
poor return for repeats under the number of 40 and increasing signal with increasing 
repeat number (Trottier et al., 1995).    
 In 1996, Mangiarini and colleagues made the next big technical advance in the 
pathway to the discovery of mHtt aggregates.  They created the R6/1 and R6/2 lines of 
HD transgenic mice using the human promoter and exon-1 of the HD gene (Mangiarini 
et al., 1996).  cDNA was generated using E.Coli and this was microinjected into single 
cell CBAxC57B/L6 embryos (Mangiarini et al., 1996).  Using this technique the 
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researchers created two viable lines, R6/1 and R6/2, with the former containing 116 
CAG repeats and the latter containing 144 CAG repeats (Mangiarini et al., 1996).  The 
R6/1 and R6/2 model both showed a robust behavioral, anatomical, and 
neuropathological phenotype beginning at 4 months and 2 months of age respectively 
(Mangiarini et al., 1996).  Behaviorally the mice showed a progressive onset movement 
phenotype including limb dyskinesia and tremor (Mangiarini et al., 1996).  They also 
showed a progressive onset of weight loss and increase in urinary incontinence 
(Mangiarini et al., 1996).  Neuropathlogically the model showed a decrease in brain 
weight, and a tendency to undergo handling induced epileptic seizures (Mangiarini et 
al., 1996).  The R6/1 and R6/2 model of HD display the most comprehensive phenotype 
of any of the developed transgenic or knock-in models of HD produced thus far, and as 
such has been used most extensively of all the models in HD research.  Development of 
this model would play a key role in not only the discovery of aggregates but also in the 
path of HD research. 
 In 1997 Davies and colleagues set out to determine the neuropathological 
characteristics of the R6/1 and R6/2 transgenic models created by Mangiarini (1996).  
Reverse transcription PCR showed ubiquitous expression of the transgene in both lines 
as consistent with previous findings regarding expression of Htt in humans (Davies et 
al., 1997).  Using the both N-terminal antibodies described above and the mAB1c2 
antibody, western blot analysis was able to detect the presence of large protein 
fragments consistent with the size of exon-1 of mHtt (Davies et al., 1997).  Using 
immunohistochemical methods the researchers discovered densely stained circular  
“inclusions” in the nuclei of neurons of the striatum, cortex, cerebellum, and spinal cord 
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with a much lower incidence in the hippocampus, thalamus, globus pallidus, and 
substantia nigra of the R6/1 and R6/2 models (Davies et al., 1997).  Ultrastructural 
analysis showed that the inclusions formed a distinct area within the nucleus separate 
from the nucleolus, and occasionally transited the nuclear membrane (Davies et al., 
1997).  For this reason the researchers coined these structures as neuronal intranuclear 
inclusions (NIIs) (Davies et al., 1997).  Secondary staining with toluidine blue in the 
striatum shows the NIIs as a circular plate like granular structure that is larger than the 
nucleolus and occurs in 1 in 5 neurons (Davies et al., 1997).  Ultrastructural analysis 
also revealed a sharp increase in the number of nuclear membrane indentations and 
increase in the number of nuclear membrane pores (Davies et al., 1997).  Staining for 
ubiquitin also showed that NIIs contain a large amount of ubiquitin (Davies et al., 1997).  
Formation of NIIs happened within 3.5 weeks of age in the cortex and 4.5 weeks of age 
in the striatum of R6/2 mice, with a pattern of increasing size and density for neurons of 
the cortex, striatum, cerebellum, and spinal cord (Davies et al., 1997).  In the striatum 
the researchers failed to find NIIs in large cholinergic interneurons or NADPH-
diaphorase-containing interneurons (Davies et al., 1997).  This study was the first to 
demonstrate in vivo aggregation of mHtt, and further describe its characteristic 
localization to the nucleus.  The implication of this finding is that the aberrant 
aggregation of mHtt protein fragments participates in some gain of pathological function 
in the affected neurons.  Transcriptional dysregulation seems to be a major pathological 
mechanism associated with NIIs.   
 One month later this group published a follow up study using similar methods in 
human HD brain tissue (DiFiglia et al., 1997).  Using the Ab1 antibody which is specific 
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for the N-terminal segment of Htt and mHtt, the researchers found significant distribution 
of NIIs in the striatum, and all layers of the cortex, but not in globus pallidus or 
cerebellum in patients with HD when compared with control brains (DiFiglia et al., 
1997).  NIIs were again found to be prominent inside of the nuclear membrane and 
larger than the nucleolus (DiFiglia et al., 1997).  Another important discovery was that 
processes were also labeled with aggregates assuming a spherical or ovoid shape in 
the neuropil of the cortex (DiFiglia et al., 1997).  These areas were coined huntingtin 
dystrophic neurites (hDNs) (DiFiglia et al., 1997).   
 Attempts to stain these aggregates with the antibody Ab585 targeted at an 
internal segment of mHtt failed, suggesting that the aggregates are formed from a 
cleavage product of the full length mHtt protein containing only the N-terminal region 
(DiFiglia et al., 1997).   Follow up western blot analysis found that in human HD cortical 
homogenates Ab1 detected a 350kD product consistent with polyQ mHtt, as well as a 
40kD product that was not present in controls (DiFiglia et al., 1997).  In an earlier study, 
researchers subjected mHtt expressing cells to cytosolic extracts of chicken hepatoma 
cells in apoptosis (Goldberg et al., 1996).  Using a substrate analog inhibitor they were 
able to block mHtt cleavage by apopain (also known as caspase-3) proteases where 
others had no effect (Goldberg et al., 1996).  Further using the same technique in cells 
expressing truncated mHtt cDNAs they determined that the protease cleaved mHtt in 
the N-terminal region, which contains multiple DXXD recognition sites for apopain 
leading to several different cleavage product sizes (Goldberg et al., 1996).  One of 
these products was approximately 50kD, which is very similar to the product size found 
by DiFiglia et al., (1997).  In mammalian cells expressing mHtt with variable polyQ 
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lengths, apoptosis was induced, and the researchers found that an increase in polyQ 
length increased dramatically the rate of apopain induced cleavage of mHtt (Goldberg et 
al., 1996) suggesting the idea that longer polyQ expansions lead to secondary 
structures in which the amino acid cleavage sites, DXXD, are more readily exposed to 
the protease.  Treatment of R6/2 mice with the caspase-3 inhibitor minocyclin has been 
shown to delay the onset of rotarod performance deficits and increase life span by 14% 
when compared with controls (M. Chen et al., 2000).   Apopain has been shown to be 
necessary for proper apoptosis in mammalian cells through ubiquitin mediated lysis 
(Nicholson et al., 1995).   
 A more recent study has shown that apopain (caspase-3) may not be necessary 
for improper neuronal degeneration.  Lines of mice were generated expressing a full 
length human mHtt gene via the introduction of a yeast artificial chromosome that had 
either its caspase-3 or caspase-6 cleavage sites altered as not to be recognized by the 
proteases (Graham et al., 2006).  Results show that caspase-3 resistant mice do not 
differ significantly from controls in neurodegeneration in the striatum, formation of NIIs, 
or performance in motor tasks (Graham et al., 2006).  However, mice expressing mHtt 
resistant for caspase-6 cleavage site showed no degeneration in the striatum, motor 
performance on par with non-carrier HD mice, and morphologically different aggregate 
formation (Graham et al., 2006).  This study was carried out to 10 months for all models 
involved including HD non-carriers and the YAC128 (HD53) model of HD.  It should be 
noted that mortality times were not reported, however YAC128 (HD53) which were 
essentially used as controls in this study have a much longer life expectancy than R6/2 
models.  On the one hand this can also be considered a strength of this study.  Given 
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the limited life-span of R6/2 models (Approximately 3-4 months), the experimenters 
were able to show that resistance to caspase-6 cleavage essentially produced a 
phenotype similar to non-carrier mice for an extended time period.  This line of research 
implicates the importance of cleavage of mHtt.  On the one hand mHtt can be cleaved 
by different proteases including apopain (caspase-3) (Goldberg et al., 1996), as well as 
calpain (Y. J. Kim et al., 2001), and most likely others that have yet to be identified.   
Each proteolytic event can cause different sized N-terminal fragments, and thus can 
regulate the behavior of the aggregate formation.  As pointed out by Graham et al., 
(2006) other fragments not cleaved at the caspase-6 sites were still present in the 
nucleus, however the phenotype suggested no dysfunction.  This finding may suggest 
that regulation of mHtt cleavage may be responsible for formation of toxic fragements 
versus products that may have no effect or are further targeted for degradation in the 
cell.   
Aggregates as Neuroprotective 
 One of the biggest questions in HD research is the functional consequence of 
aggregate formation.  On the one hand there are copious amounts of research to 
indicate that the formation of aggregates is pathological and one of the main reasons for 
the dysfunction and neurodegeneration seen in HD.  However, there are lines of 
evidence that also suggest that formation of aggregates is a neuroprotective response.   
 One group of researchers transfected cultured striatal neurons with mouse N-
terminal fragments containing either 17 or 68 Q repeats (Saudou et al., 1998).  They 
found that there was an increase in NIIs in cells that had been exposed to trophic 
factors but that this resulted in a much lower rate of cellular apoptosis compared with 
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cells that did not receive trophic support (Saudou et al., 1998).  This line of evidence 
shows an increase in location of aggregates to the nucleus with no increase in cell 
death.  
 In another study, researchers created an automated microscopy procedure to 
follow striatal neurons in culture that had been transfected with GFP-tagged N-terminal 
mHtt fragments (Arrasate, Mitra, Schweitzer, Segal, & Finkbeiner, 2004).  They found 
that cells transfected with mHtt N-terminal fragments die in a fashion that is dependent 
upon length of Q repeat, such that longer polyQ expansions lead to a quicker cell death, 
which was expected (Arrasate et al., 2004).  However, they also found that neurons 
forming inclusion bodies (authors choice of terminology, analogous to NIIs) were less 
likely to die, and that cells with a diffuse fluorescent return for N-terminal fragments 
were much more likely to die quickly (Arrasate et al., 2004).  This would suggest that the 
aggregation and formation of NIIs would play some part in potentially protecting the cell 
from mHtt.   
 The researchers responsible for creating the YAC128 mouse model of HD which 
expresses a full length human htt gene under the control of the human promoter, also 
inadvertently created a mouse expressing exon-1 and exon-2 of the same gene through 
accidental truncation of the yeast artificial chromosome during recombination (Slow et 
al., 2005).  This ShortStop model was found to widely express the N-terminal fragment, 
and at 12 months of age showed NIIs in 95% of neurons of the striatum (Slow et al., 
2005).  However, when compared to YAC128 mice, the ShortStop mice showed no 
neurodegeneration, no detriment to rotarod performance, and a much longer life span 
(Duan et al., 2008).  Despite the very robust formation of NIIs these mice did not display 
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the same phenotype of mice created in a similar fashion that express the full length 
mHtt gene.  The authors suggest that maybe this is the inability of the ShortStop 
specific fragment to undergo caspase cleavage at a site that will in turn cause a toxic 
cycle (Slow et al., 2005).   This is important because it shows that NIIs do not 
necessarily signal cell death. 
 Clearly the biggest argument for a neuroprotective role of aggregates is quite 
obvious in that the expression of mHtt in the brain is ubiquitous, however many parts of 
the brain are spared whereas the striatum, and to a lesser degree the cortex, show the 
greatest amount of neurodegeneration.  Why then are other areas of the brain not 
affected by HD?   For the sake of current research in HD, it is beneficial at this point to 
assume that both possibilities are true.  On the one hand the formation of aggregates is 
a cellular response that is an attempt of the cell to deal with toxic mHtt or toxic mHtt 
fragments.  This would serve multiple useful purposes in the cell including removing 
mHtt from the cytosol in turn limiting its interference with mitochondria and secretory 
structures, and providing an aggregated target for degradation via proteolysis.  On the 
other hand, it may be that the cell cannot properly regulate the lysing of the proteins, 
and by transporting the large aggregates into the nucleus, it begin to cause further 
disruptions to transcription.  Support for why this may be the case might come by the 
investigation of the small GTPase Rhes which is selectively expressed in the striatum.   
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Rhes 
Ras homolog enriched in striatum (Rhes) is a small GTP binding protein that is 
heavily expressed in the striatum and has a high degree of nucleotide conservation with 
the Ras superfamily of small GTPase proteins (Errico et al., 2008; J. Falk et al., 1999; 
Harrison & LaHoste, 2006a).  Ras superfamily members act as cellular switching 
mechanisms that interact with other effector proteins to change specific cellular 
messaging systems within the intracellular cytoplasmic domain (Campbell, Khosravi-
Far, Rossman, Clark, & Der, 1998).  Ras superfamily members have been studied 
extensively for their role in the activation of the mitogen-activated protein 
kinase/extracellular signal-related kinase (MAPK/ERK) signaling pathway which is 
intimately involved in cell proliferation and implicated in the mechanics of many cancers 
(Bos, 1989; Campbell et al., 1998; Rodriquez-Viciana, Sabatier, & McCormick, 2004).  
However, despite the large body of research conducted on the relationship between the 
MAPK/ERK signaling pathways and small GTPases, Rhes has not been shown to affect 
MAPK/ERK signaling (Vargiu et al., 2004).   
Rhes was originally characterized by Falk and colleagues after the discovery of 
its very closely related family member Dexras1/AGS1 (1999).  In bacterial cells 
expressing Rhes, these researchers determined that Rhes did bind GTP likely giving it 
intrinsic GTPase activity, and that it was induced by thyroid hormone unlike its close 
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relative Dexras1, which is induced by dexamethasone.  This group also made the 
observation that like Dexras1, Rhes also contained an unusually long c-terminus, the 
part of the protein that is known to associate with other proteins, making it likely that 
these proteins possess unique but similar signaling characteristics (J. Falk et al., 1999).   
Vargiu and colleagues further characterized Rhes (2004).  In situ hybridization 
was performed and it was determined that the Rhes mRNA was heavily expressed in 
the striatum, but to a lesser extent in the nucleus accumbens, olfactory bulb, olfactory 
tubercle, piriform cortex, hippocampus, anterior thalamic nuclei, inferior colliculus, 
cerebellum, cortex, and outside of the CNS in the thyroid.  A later study provided 
evidence that expression of Rhes is determined by dopamine 33xpression3333.  By 
experimentally lesioning dopaminergic projections, a decrease in Rhes mRNA was 
measured in the caudate putamen and shell of Nac suggesting that Rhes expression is 
regulated by dopaminergic tone and also that supersentivity of dopamine receptors 
correlates with Rhes mRNA downregulation (Harrison & LaHoste, 2006b).    
By attaching a GFP (green fluorescent protein) to the CAAX terminal, an area of 
proteins susceptible to membrane binding, researchers were able to determine that 
Rhes is targeted to the plasma membrane in vitro. Through a series of pharmacological 
interventions it was also determined that farnesylation is the most likely candidate for its 
post translational targeting to the membrane (Vargiu et al., 2004).  
 In vitro immuno-precipitation showed evidence that Rhes did not stimulate the 
MAPK/ERK pathway, but that it did stimulate the phosphoinositide 3-kinase (PI3K) 
pathway (Vargiu et al., 2004).  In vitro GTP binding found that 30% of Rhes is 
constitutively bound by GTP, meaning its effects remain active at basal conditions.  
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Evidence also suggest an inability of guanidine exchange factors (GEFs), small proteins 
that assist in exchanging GTP and GDP molecules on other proteins, to alter GTP 
binding.  Most importantly, Rhes was found to inhibit cAMP concentration in cells 
expressing the metabotropic, Gαs coupled, thyroid hormone receptor, suggesting that 
Rhes interferes with signaling of Gαs coupled receptors (Vargiu et al., 2004).   This was 
supported by Errico et al (2008), who found that protein kinase A-dependent 
phosphorylation of the GluR1 subunit of the AMPA receptor in medium spiny neurons, a 
direct result of Gαs/olf stimulation of AC/cAMP, was increased in Rhes-/- primary cultures 
(2008).  Since this phosphorylation is a direct result of Gαs/olf stimulation of adenylyl 
cyclase (AC) and cAMP it suggests that Rhes provides negative modulation of the Gαs/olf 
stimulation of AC.  A later study showed that Rhes interacts directly with D1 receptor 
signaling at the level of AC.  In Chinese hamster ovary cells transfected with D1 
receptors and Rhes, stimulation with the D1 receptor agonist SKF 83822 resulted in an 
attenuation of cAMP accumulation in a pertussis toxin sensitive manner, whereas 
stimulation of AC with forskolin failed to attenuate cAMP accumulation suggesting that 
Rhes interacts with the ability of Gαs/olf to be activated by the receptor (Harrison & He, 
2011).   
To determine if Rhes modifies Gαi/o signaling like its closest relative Dexras1, 
researchers using PC12 cells transfected with Rhes and the M2-muscarinic receptor 
found no change in reporter activity suggesting no alteration of Gαi/o  (Vargiu et al., 
2004).  Errico et al. suggested that Rhes may have an effect on Gαi/o signaling after 
finding that in Rhes-/- primary cultures of striatal medium spiny neurons, lack of Rhes 
significantly lowered the ability of GTP to bind Gαi/o in agonist stimulated D2 receptors 
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(2008).  A later study found that Rhes does influence signaling through Gαi/o.  Cells 
stably expressing the M2-muscarinic receptor were shown to produce maximal inhibition 
of Cav2.2 channels under agonist stimulation when transfected with mutant Rhes, 
however agonist stimulation produced less inhibition in the presence of fully functioning 
Rhes, suggesting that Rhes attenuated Gαi/o inhibitory signaling (Thapliyal, Bannister, 
Christopher, & Brett, 2008).  Harrison and He (2011) also hypothesized that since Rhes 
acts to decrease cAMP accumulation in a pertussin toxin sensitive manner that it might 
be involved with activation of Gαi/o.  Pull down assays showed that Rhes did in fact 
interact with Gαi/o, but only in its GTP bound form (Harrison & He, 2011).  Rhes did not 
show any ability to affect cAMP accumulation through stimulation of D2 receptors with 
the agonist quinpirole (Harrison & He, 2011).   
Another important finding of the previously mentioned study was the possible role 
of Rhes’ effect on Gβγ signaling.   This group transfected M2-muscarinic receptor 
expressing cells with Rhes and showed tonic inhibition of Cav2.2 channels, a Gβγ 
mediated effect, versus cells transfected with a Rhes CAAX mutated control (Thapliyal 
et al., 2008).  In a recent study by Hill, Goddard, Ladds, and Davey (2009), cells 
expressing both Rhes and either Gβ1, Gβ2, Gβ3, Gβ4, or Gβ5 were compared, and it was 
found that Rhes showed much more binding affinity for Gβ1-3, but not Gβ4,5 .  These 
results show evidence that Rhes could possibly interfere with Gαs binding due to its 
affinity to interact with Gβ1-3, the units that preferentially bind Gαs, and not Gβ4,5, units 
that preferentially bind Gαi/o.  Hill et al. suggests this might be possible due to the fact 
that Gαs interaction with the plasma membrane is much weaker than that of Gαi/o, 
therefore Gαi/o subunits are able to overcome the interference of Rhes in binding Gβ 
36 
 
subunits (2009).  This would lend support to the assertion of Thalapiyal et al. (2008) that 
Rhes may interfere with Gαi/o signaling by allowing the Gαi/o subunit to disassociate from 
the heterotrimeric complex and signal but as this happens allowing Rhes to bind the Gβγ 
subunits disrupting re-association of the Gαi/o subunit with the Gβγ complex.  They 
suggest that this may be due to the ability of Rhes to function as a guanidine exchange 
factor for Gαi/o (Thapliyal et al., 2008).    
Rhes has also been shown to effect opioid signaling as well.  We conducted an 
experiment to determine the effects of Rhes on opioid analgesia, tolerance, and 
withdrawal (Lee et al., 2011).  Mice lacking Rhes showed a marked increase in opioid-
mediated analgesia, no significant development of tolerance with repeated exposure to 
morphine, and a much milder withdrawal phenotype when compared with controls (Lee 
et al., 2011).  These results were in stark contrast to the hypothesis that lack of Rhes 
would increase cAMP production through activation of Gs while simultaneously 
decreasing the ability of Gi/o to decrease AC-mediated cAMP increases, the 
predominant mechanism by which µ-opioid receptors work to decrease neuronal 
excitability.  An earlier study had shown that Rhes-/- mice show a decrease in D1 
receptor-mediated grooming when compared with Rhes+/+ mice which is a 
phospholipase C (PLC) –mediated behavior (Quintero, Spano, LaHoste, & Harrison, 
2008).  Likewise there is evidence that µ-opioid-mediated analgesia (Bonacci et al., 
2006 ; Mathews, Smrcka, & Bidlack, 2008; Newton et al., 2007; W. Xie et al., 1999) as 
well as tolerance and withdrawal (Mathews et al., 2008; Smith, Lohmann, & Dewey, 
1999; Zeitz, Malmberg, Gilbert, & Basbaum, 2001) are mediated by PLC-PKC (protein 
kinase C) dependent mechanisms.  The evidence from this study points to the activation 
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of a pro-nociceptive pathway by which Rhes promotes the signaling of µ -opioid 
receptor associated Gβγ subunits increasing activation of the PLC-PKC pathways.   All of 
these results considered together show that Rhes has a highly important role in signal 
transduction within the striatum.   
The Role of Rhes in HD 
Rhes has also been found to play an important role in the pathogenesis of HD.  
In a series of experiments, Subramaniam and colleagues set out to determine if this 
striatally specific protein could in fact be responsible for much of the neurodegeneration 
that is striatally specific in HD.  In cells expressing mHtt and Rhes, it was found that 
Rhes bound mHtt, and with a much higher affinity than Htt, while not binding a similar 
protein, ataxin, containing a polyQ repeat (Subramaniam, Sixt, Barrow, & Snyder, 
2009).  In cells expressing Rhes and mHtt together, it was shown that there was a 60% 
decline in cell survival when compared with cells expressing either Rhes or mHtt alone, 
or Rhes with Htt (Subramaniam et al., 2009).  They were able to reduce apoptosis in 
PC12 cells, which contain endogenous Rhes, expressing mHtt by use of RNA- 
interference directed at Rhes expression (Subramaniam et al., 2009).  They determined 
that overexpression of Rhes in vitro lead to an increase in soluble mHtt, an increase in 
SUMOylation of mHtt, and a decrease in ubiquitination of mHtt (Subramaniam et al., 
2009).  Targeted mutation of lysine residues in mHtt involved in SUMOylation resulted 
in a decrease in SUMOylation, a decrease in mHtt dis-aggregation, and a reversal in 
cytotoxicity (Subramaniam et al., 2009).   They further determined that Rhes did directly 
bind the SUMO-conjugating enzyme/E2 ligase Ubc-9 and itself was SUMOylated 
(Subramaniam et al., 2009).  Mutation of the CAAX prenylation/farnesylation site on 
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Rhes but not mutation of the GTPase catalytic core was sufficient to reverse the pattern 
of SUMOylation seen at mHtt suggesting that Rhes’ association with the membrane was 
critical to the process whereas its GTPase activity was not required for SUMOylation of 
mHtt (Subramaniam et al., 2009).   
The biochemical sequencing for the attachment of both ubiquitin and SUMO 
follow a very similar pathway in which 2 or 3 steps are involved.  First, E1 SUMO 
activating enzyme complex is formed with SUMO (Hay, 2005).  Next, SUMO is 
transferred to Ubc-9 which is known as the conjugating protein and from here can be 
directly ligated to the target protein (Hay, 2005).  However, although SUMOylation can 
occur at the last step, in many cases an E3 ligase must be present (Hay, 2005).  E3 
ligases form an intermediate for the ligation reaction and can increase its efficiency 
(Hay, 2005).   Evidence from this experiment suggests that Rhes acts in this last ligating 
step similar to other E3 ligases, and therefore provides a critical intermediate function in 
the SUMOylation of mHtt (Subramaniam et al., 2009).  A follow up study by 
Subramaniam and colleagues also found that Rhes acts as an important striatal 
regulator of SUMOylation (Subramaniam et al., 2010).  They found a major decrease in 
the SUMOylation of common SUMO targets Ubc-9, SP100, RanGAP1, and IkB in the 
striatum of Rhes-/- mice (Subramaniam et al., 2010).  Importantly they found that Rhes 
increased the cross thioester transfer of SUMO between E1 and Ubc-9 up to 400% 
(Subramaniam et al., 2010).   
Small ubiquitin-like modifier (SUMO) is a protein that shares a 20% sequence 
homology with ubiquitin and has been shown to be involved in many cellular processes 
by acting to direct the fate of proteins by modifying them and subsequently being 
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removed (Hay, 2005).  SUMO requires a specialized binding domain in which it is 
covalently bonded to a lysine which is preceded by a large hydrophobic residue and 
followed by any amino acid, and finally followed by glutamic acid (Hay, 2005).  Ubiquitin 
on the other hand can recognize a variety of binding domains (Hurley, Lee, & Prag, 
2006), however they share this binding site in mHtt (Steffan et al., 2004).  In vitro 
experiments in which either mHtt or SUMO were mutated to block binding sites showed 
a variety of interesting results (Steffan et al., 2004).  First, it was shown that by 
permanently SUMOylating mHtt resulted in de-aggregation of mHtt and an increase in 
non-aggregated mHtt localization to the cystosol (Steffan et al., 2004).  They also found 
that SUMOylated mHtt shows a greater suppressive effect on a number of promoters 
potentially giving mHtt a greater transcriptional suppressive effect (Steffan et al., 2004).  
Lastly, they showed that genetic mutation of SUMO in drosophila models of HD showed 
a much decreased neuropathological phenotype as compared to controls (Steffan et al., 
2004).  As Hay (2005) points out in his review of SUMO, one of its functions is as an 
antagonist of ubiquitin activity.  It has already been mentioned that ubiquitin is highly 
colocalized with HD aggregates in vivo (Davies et al., 1997).   
Recently in our laboratory we have found in vivo evidence to support the role of 
Rhes in SUMOylation induced pathogenesis.  Rhes-/- mice were successfully cross-bred 
with R6/1 mice.  Behavioral and neuroanatomical phenotypes were observed for the 
mice throughout their lifespan.  It was found that Rhes-/-/HD+ mice show significant 
decreases in motor symptomology compared to Rhes+/+/HD+ mice, and were identical to 
controls up to 5 months of age (Baiamonte, Lee, Brewer, Spano, & LaHoste, 2013).  
Measures of brain weight and size were inconclusive, but this is most likely due to the 
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fact that Rhes-/- show a diminished brain weight and size analogous to HD+ mice.  No 
significant differences were found between brain weight and size of Rhes-/-/HD+ when 
compared to Rhes+/+/HD+ mice.  Overall this behavioral evidence supports the assertion 
that Rhes acts as an E3 ligase for SUMOylation of mHtt, therefore deletion of Rhes in 
vivo results in a decrease in striatal neurodegeneration.  Interestingly the Rhes-/-/HD+ 
mice do begin to show a progressive onset of HD phenotype although not as severe as 
Rhes+/+/HD+, but this is delayed until 5+ months.  This may also lend support to the idea 
that progressive aggregate formation begins as a neuroprotective cellular event, and 
eventually causes problems that lead to eventual degeneration.   
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Hypothesis 
 Some researchers (e.g., Subramaniam et al., 2009; 2010) have argued that 
increased levels of soluble, cytosolic mHtt are toxic to neurons that express Rhes.  In 
this scenario, the formation of intranuclear aggregates (NIIs) is neuro-protective by 
virtue of sequestering the mutant protein, thereby decreasing the levels of cytosolic, 
toxic mHtt. 
 We hypothesize that Rhes will significantly affect the time at which mHtt 
aggregates appear in striatal neurons such that Rhes deleted mice will have an earlier 
onset of aggregate formation when compared to their wild type counterparts suffering 
from HD.  In addition, we propose that the timing of aggregate formation will be 
significantly correlated with the appearance of deficits in motor behavior. Specifically we 
predict that aggregate formation will not be a predictor of disease phenotype in Rhes 
deleted mice. This prediction is based on our previous research showing that the 
emergence of motor deficits is correlated with Rhes expression in a gene-dose manner 
(Baiamonte et. al., 2012).  
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Design and Methods 
Animals 
 All procedures carried out in this study were done under the approval and 
supervision of the University of New Orleans Institutional Animal Care and Use 
Committee (Approval #UNO-12-007) and the United States Public Health Service.  
All Rhes mice used in this study have from breeding pairs generously donated by 
Dr. Daniela Spano.  Mice were created on a CD1 and C57BL/6 background. Using site-
specific homologous recombination, a null mutation was created at the Rhes locus 
resulting in a strain of mice null for the Rhes gene.  An EGFP cassette was inserted into 
the locus of the Rhes gene allowing access to a reporter gene for genotyping.   
For this study we chose the R6/1 transgenic murine model of Huntington’s 
disease.  One male founder was shown to have integrated the transgene at one site 
allowing for ubiquitous expression of an N-terminal mHtt fragment containing a 116 
CAG repeat sequence.  Proven R6/1 breeders were purchased from The Jackson 
Laboratory (Jackson Laboratories, Bar Harbor, Maine, USA).  These breeders were 
back crossed on a C57BL/6J background for at least 10 generations.   
Tail Biopsy 
 Tail biopsies were performed on all mice to render a sample of DNA for 
genotyping.  Mice were anesthetized using 100-150 mg/kg of a ketamine/xylazine 
solution.  Depth of anesthesia was checked using toe pinch and corneal reflex.  Once 
the animal displayed no reflex, the distal 2-5 mm of its tail was clipped using a straight 
razor, and the site was cauterized using a razor blade heated over a spirit lamp.  
Animals were monitored until they had fully recovered from anesthesia.  The tail clip 
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was placed in a solution containing 300μl of DirectPCR™ lysis reagents and 11.6μl of 
proteinase K solution (Viagen BioTech, Los Angeles, California, USA).  Samples were 
placed on rotation in an incubator at 55˚C overnight to allow for complete cell lysis.   
Polymerase Chain Reaction 
 After tail samples were incubated at 55˚C overnight, they were placed in an oven 
at 85˚c for approximately 1 hour to deactivate the proteinase K.  For the rhes gene, 
reactions were prepared consisting of 12.5μl GoTaq Green Master Mix™ (Promega, 
Madison, Wisconsin, USA), 3μl of sense and antisense primers, 11.5μl of nuclease free 
water, and 0.5μl of DNA sample.  Primers for the wild type gene include upstream 5’-
TCCTAGCTCAGCGAGAGGAA-3’, and downstream 5’-
CTAGACAGGGCCCACAGAGA-3’.  Primers for the EGFP reporter include 5’-
CCTACGGCGTGCAGTGCTTCAGC-3’, and 5’-GCGAGCTGCACGCTGCGTCCTC-3’.  
Reactions using WT primers were allowed to anneal at 60˚C for 30 seconds with a 1 
minute extension time, while EGFP reactions were allowed to anneal at 55˚C for 30 
seconds with a 1 minute extension time.  Both reactions were allowed to complete 35 
cycles and then held at 4˚C to stop the reaction.  Reactions for the mHtt allele were 
mixed using 12.5μl GoTaq Green Master Mix™, 3μl of sense and antisense primers, 
9.5μl of nuclease free water, and 2.0μl of DNA sample.  Primers for the HD transgene 
segment include 5’-CCGCTCAGGTTCTGCTTTT-3’ and 5’-
TGGAAGGACTTGAGGGAC-3’.  The HD reaction was allowed to anneal at 55˚C for 1 
minute with an extension time of 1 minute for 31 cycles and subsequently held at 4˚C.    
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Gel Electrophoresis 
 Gel electrophoresis was carried out using a 3% agarose gel.  5μl of each PCR 
reaction sample was placed in each well.  A 100bp ladder was used at the distal wells of 
the gel providing a standard to judge the length of the alleles.  Samples were run 
through the gel for 5 minutes at 35v to allow the DNA to move into the gel evenly.  After 
the initial 5 minutes the voltage was increased to 95v, and the DNA was allowed to run 
until the marker dyes approached the edge of the gel.  The gel was post-stained using a 
0.5μg/ml solution of ethidium bromide.  The gel was then imaged using a standard 
fluorescent light box.  Expected size of the wild type gene was 400bp, while expected 
size of the EGFP reporter was 345bp.  Expected size of the HD transgene was 305bp.   
Preparation of Brain Tissue 
 
 At the specified experimental time points mice were taken from their cages live 
and promptly sacrificed by decapitation.  Whole brains were harvested and flash frozen 
by immersion in -80˚C isopentane for at least 5 minutes. Brains were then wrapped in 
aluminum foil and stored at -80˚C.  Prior to sectioning, the brains were placed in the 
cryostat at -20˚C and allowed to equilibrate to that temperature for a minimum of 2 
hours.  Brains were sliced on the coronal plane at 20 microns and sections were 
mounted onto gelatin treated microscope slides.  Slices were selected for mounting 
once the corpus collosum began to cross the midline and terminated with the upturning 
of the lateral edges of the anterior commissar.  This allowed for reliable sectioning of the 
striatum.   
 Once slides were removed from the cryostat they were left at room temperature 
for 5 minutes.  After five minutes the slides were incubated in 4% paraformaldehyde for 
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10 minutes.  This was followed by a rinse in 0.1M phosphate buffered saline (PBS) for 5 
minutes and a final rinse in deionized water for 5 minutes. Slides were air dried then 
placed in a slide mailer and stored at -80˚C.   
Immunohistochemistry  
Day 1  
 All wash steps, unless otherwise specified, included 3 successive rinses for ten 
minutes each in 0.1M PBS.  Slides were first placed in a solution of 0.1M PBS and 0.3% 
hydrogen peroxide for 30 minutes to allow for any endogenous peroxidase activity to be 
extinguished.  Slides were then washed.  Following this wash, the tissue was allowed to 
incubate for 60 minutes in a solution of 0.1M PBS, and 5% normal horse serum.  This 
step served to block non-specific binding sites of the primary antibody.  Following this 
blocking procedure the slides were again washed.   The slides were then incubated for 
48 hours at room temperature in a solution containing 0.1M PBS, 1% normal horse 
serum and mouse monoclonal anti-Huntingtin antibody (em48, 1:200) which 
preferentially recognizes the aggregated form of mHtt.   
Day 2 
 After 48 hours of incubation in the primary antibody, the slides were again 
washed.  They were then allowed to incubate for 1 hour in a solution containing 0.1M 
PBS, 1% normal horse serum, and biotinylated horse anti-mouse IgG secondary 
antibody at a dilution of 1:200.   The slides were then washed.  They were then 
incubated for 1 hour in a solution containing an avidin and biotinylated horseradish 
peroxidase macromolecular complex (Elite ABC reagent, Vectastain, Burlingame, CA, 
USA).  Slides were washed again.  After this wash the slides were stained for 
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approximately 6 minutes using the DAB staining kit (Vectastain, Burlingame, CA, USA) 
which consists of 3,3’-diaminobenzidine, hydrogen peroxide, and nickel chloride in 
distilled water.  Immediately following staining the slides were washed in distilled water 
and allowed to air dry.  After drying slides, glass cover slips were mounted on top of the 
tissue sections using a large drop of Histomount on each section (National Diagnostics, 
Atlanta, Georgia, USA).  Slides were allowed to dry and harden for 24 hours.  
 Slides were analyzed using an Olympus BX 60 light microscope (Center Valley, 
Pennsylvania, USA).  Images for each slide were captured and digitized at 400x 
objective representing a volume of 400um.  The images were selected from the right 
and left caudate.  Matlab (Natick, Massachussets, USA) was used to analyze the 
images.  Coding scripts were generated to account for image intensity variability.  The 
gray scale intensity histogram of a representative slice was selected and analyzed.  The 
values defining the histogram were then applied to all other slides using an automated 
script applying the ‘imhistmatch’ function to account for differences in exposure and 
lighting that occurred during image capturing.  Once the images were standardized 
another script was generated to detect aggregates.  This function was defined based on 
circular centers, radii of 1-8 pixels, and intensity.  Aggregates were defined as intensity 
values < X based on darkness against a light background Y.    
Motor Performance 
The Rotarod apparatus (Med Associates Inc., Georgia, Vermont, USA.) was 
used to assess motor performance in all animals. The rotating speed of the rod was set 
at 16 rpm (rotations per minute) throughout testing and each mouse was given one day 
of habituation and 1 day of testing.  Testing was similar to the procedure outlined by 
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Stack et al. (2005) and was conducted once on each group before they were sacrificed 
at 2 months, 4 months, and 6 months respectively.  During habituation and testing trials, 
the animals were placed on the rotarod and the latency to fall off the rod was recorded.  
If animals remained on the rod after 60 sec had elapsed, they were promptly removed 
and given a maximum score of 60.  This procedure was conducted for 3 trials per day 
for each animal with a 60 sec resting period between each trial.  The maximum rotarod 
score per day for each animal was 180. 
Clasping 
Whereas normal mice splay their limbs outward when suspended by their tails, 
animals suffering from HD have the tendency to clasp their limbs inward towards their 
body (Mangiarini et al., 1996; Rubinsztein, 2002).  This behavior is considered to be a 
sign of muscle dystonia in HD models (Ferrante, 2009).  Clasping was assessed 
according to Stack et al. (2005) immediately after testing of motor performance on the 
rotarod.  Quantification of clasping entailed 3 trials of suspending the animal in the air 
by the tail for 10 seconds, during which the number of limbs withdrawn was recorded.  
Each limb was scored as a 1 if the mouse clasped the limb into the body and was 
scored a 0 if the limb remained extended away from the body.  The maximum score per 
trial for each mouse was 4 and a total score of 12 for each day.  Animals were allowed a 
10 sec resting period between each trial.  Similar to the other tasks in the study, each 
animal was given a habituation day.     
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Experimental Design        
 Experimental animals were housed with littermates on a 12hr light dark cycle and 
provided food and water ad libitum.  A total of N = 29 mice were used.  HD+ mice were 
cross-bred with Rhes+/- mice to produce groups of HD+ mice that were either Rhes-
normal (Rhes+/+/HD+) or Rhes heterozygotes (Rhes+/-/HD+).  All subsequent crosses 
were made using Rhes+/-/HD+ producing one of three genotypes (Rhes+/-/HD+ , 
Rhes+/+/HD+ , or Rhes-/-/HD+).  Limitations in the viability of offspring for Rhes x HD 
crosses resulted in a total n=9 Rhes-/-/HD+ and n=17  Rhes+/+/HD+ mice available for 
study.  Given the previous research performed showing a gene dosing effect 
(Baiamonte, 2012) and lack of available Rhes-/-/HD+ mice, an n=3 Rhes+/-/HD+ were 
used at the 2 month time period.  At this time point it was expected a priori that there 
would be no difference in genotypes. Each genotype was divided into 3 sub-groups 
according to the time of testing and sacrifice: 2, 4, and 6 months of age.  These time 
points were chosen based on previous work that shows lack of symptomology between 
these genotypes at 2 months, with significant variation at 4 months, and symptomology 
in all groups at 6 months of age (Baiamonte et. al., 2012). 
 Differences in latency to fall from the rotarod were analyzed for each time point 
using a 2 (genotype) x 3 (time point) between-subjects factorial ANOVA.  Clasping was 
also assessed using a 2 (genotype) x 3 (time point) between-subjects factorial ANOVA.  
Presence of aggregates in the striatum was statistically analyzed using a 2 (genotype) x 
3 (time point) between subjects factorial ANOVA.  Significant omnibus tests were further 
investigated using Tukey’s HSD.  The probability of making a type-1 error was set to 
α=0.05.  Pearson’s r was calculated to determine if there was a correlation between the 
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amount of aggregates that formed over time and behavioral variables for both 
genotypes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
Results 
Aggregate Formation 
A control experiment confirmed that no staining was present in non-HD carriers 
whereas HD carriers showed numerous intranuclear aggregates in the striatum.  As 
expected aggregate formation increased with age for both genotypes [F(2,28)=86.146, p 
< 0.0005] (figure 1) and this result closely resembles the aggregation behavior observed 
in humans with HD (DiFiglia et.al., 1997).  Follow up analysis using Tukey’s HSD 
revealed that aggregate counts between 2 months of age (M=80.6 SD=29.35) did not 
significantly differ from aggregate counts at 4 months of age (M=176.5, SD=93.95).  
However, aggregate count increased dramatically at 6 months of age (M=1019, 
SD=297.11).  The number of aggregates by Rhes genotype displayed a trend toward 
significance (F(1,28)=4.008, p=0.057).  More importantly genotype had no effect on 
aggregate formation over time (F(2, 28)=1.263, p=0.302).   
Figure 1. 
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Motor Performance 
Rotarod results were consistent with the previous study (figure 2). A significant 
interaction of genotype by time point was found (F(2,28)=3.759, p=0.039).  Follow up 
comparisons of the interactions using Tukey’s HSD found that at the 2 month time 
period there was no difference between Rhes+/-/HD+ mice (M=178.67, SD=2.31) and 
Rhes+/+/HD+ mice (M=174, SD=15.87)  on latency to fall from the rotarod. At the 4 month 
time period Rhes+/+/HD+ mice (M=91.6, SD=65.47) performed significantly worse than 
Rhes-/-/HD+ mice (M=180, SD=0.0).  The same result was found at the 6 month time 
point with Rhes+/+/HD+ mice (M=29.4, SD=26.09) performing much worse than Rhes-/-
/HD+ mice (M=99, SD=40.84).  Rotarod performance was shown to steadily decrease as 
aggregate formation increased for both Rhes+/+/HD+ mice (r =-.073, n=0.001) and Rhes-/-
/HD+ mice (r =-0.82, p=0.001).   
Figure 2. 
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Clasping 
 Clasping results were consistent with the previous study as well (figure 3).  A 
significant interaction of genotype by time point was found (F(2,28)=8.8, p=0.001).  Like 
performance on the rotarod, no difference in clasping was found between Rhes+/-/HD+ 
(M=1.67, SD=2.08) and Rhes+/+/HD+ mice (M=1, SD=1.15) at 2 months.  Rhes+/+/HD+ 
mice performed significantly worse at 4 (M=5.4, SD=3.65) and 6 months (M=11, SD=1) 
when compared to Rhes-/-/HD+ mice at 4 (M=0.8, SD=1.09) and 6 months (M=3.75, 
SD=2.06).  Interestingly aggregate formation did not correlate with clasping behavior in 
Rhes-/-/HD+ mice (r =0.46, p=0.13), whereas increasing aggregate count in Rhes+/+/HD+ 
mice strongly correlated with an increase in clasping behavior (r =0.79, p<0.0001).    
 Figure 3.  
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Discussion 
 Aggregate formation in both genotypes was consistent with previously reported 
findings (Mangiarini et al., 1996).  At two months of age both genotypes displayed a 
diffuse staining of cell bodies measuring approximately 5um in length which 
corresponds to the size of MSNs (Kawaguchi, Wilson, & Emson, 1990). This diffuse 
staining is likely to be em48 tagging fragmented mHtt expressed in the cell body before 
aggregation (figure 4a).  Heavier staining can be seen in some processes which is 
consistent with other reports (figure 4b) (Mangiarini et al., 1996; Wang et al., 2008).    
Figure 4.  
 
 
 
 
 
 
 
 
 
 
At four months, soma staining is more intense, as well as staining in processes (figure 
5a). Small somatic aggregates (green arrow, figure 5b) are common and some 
aggregates can be seen localizing to the nucleus (red arrows, figure 5b).  
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Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
At six months of age there is massive intranuclear aggregation (red arrows, figure 6).  
Also, there are large areas of very intense staining that are assumed to be dystrophic 
neurites (green arrows, figure 6) which are similar to previous findings and occurred 
consistently in all 6 month old HD brains (DiFiglia et al., 1997).   
 
Figure 6.  
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 This study failed to find a significant difference in aggregate formation comparing 
Rhes deleted mice (Rhes-/-/HD+, Rhes+/-/HD+) with Rhes normal mice (Rhes+/+/HD+).  It 
was hypothesized that Rhes deleted mice would in fact show an increase in aggregation 
compared to Rhes normal mice due to evidence that Rhes acts as an e3 ligase for 
SUMOylation which hinders aggregation and promotes the stability of toxic soluble 
fragments of mHtt.  Failing to reject the null hypothesis in this particular instance raises 
far more interesting questions than rejecting it as evidence of Rhes’ role in 
neuroprotection and neuropathology has mounted.   
 The first evidence of the neuroprotective role of Rhes was provided by 
Subramaniam et.al. (2009, 2010) showing that Rhes promotes SUMOylation of mHtt 
leading to disaggregation. They also found deletion of Rhes provided an in vitro 
increase in cell survivability of mHtt transfected cells (Subramaniam et. al., 2010).  Our 
lab, in response to this finding, followed up on this in vitro work with an in vivo 
behavioral study. We showed that Rhes deleted mice show a significant delay in the 
time course of the HD phenotype providing crucial in vivo evidence that Rhes does in 
fact play a major role in HD pathogenesis (Baiamonte et al., 2013).  At the same time 
Mealer and colleagues (2013) published another report showing similar behavioral 
results in Rhes-/- mice with induced 3-nitropropionic acid lesion, a long established 
model of striatal neurodegeneration.  Subramaniam and colleagues have very recently 
published an in vivo report showing similar findings, this time using Rhes-/- mice crossed 
with the N171-82Q murine model of HD (Swarnkar et al., 2015).  Not all reports have 
been supportive of the in vivo results from the above combined studies.  One other 
group has recently published findings that are in direct contrast to the previous studies.  
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Lee and colleagues (2014) have found that suppression of Rhes using RNAi in two 
murine models of HD, N171-82Q and BacHD, did not in fact cause a significant rescue 
of behavioral symptoms.  In fact, they found that suppression of Rhes activity enhanced 
the disease phenotype (Lee et al., 2014).  A follow up study by Lee and colleagues (Lee 
et al., 2015) found that over-expressing Rhes using a viral vector in N171-82Q mice 
actually diminished the disease phenotype.  Conclusions drawn from comparisons of 
these studies should be made with caution as the methodologies used are very different 
from each other.  
 Along with these in vivo studies, new evidence of a role for Rhes’ in the cellular 
functions in HD has come to light as well.  One of the most interesting is the role of 
Rhes in mTOR (mammalian target of rapomycin) signaling.  mTOR regulates many 
important cellular processes including ATP production, protein synthesis, lipid synthesis, 
and, most importantly for HD, autophagy (Laplante & Sabatini, 2013).  Research shows 
that mTOR activation by mHtt may decrease autophagy thereby leading to an 
exacerbation of the HD phenotype (Pryor et al., 2014).  Rhes has been shown to bind 
and activate mTOR (Subramaniam et al., 2012) which leads to the assumption that 
perhaps Rhes provides a means of inhibiting autophagy and clearance of mHtt.  Rhes 
has also been implicated in Akt signaling.  One study has found that Rhes increases Akt 
targeting to the membrane (Bang, Steenstra, Kim, 2012).  Rhes deletion in vivo has also 
been shown to increase Akt phosphorylation (Harrison, Muller, & Spano, 2013).  Akt is 
an upstream regulator of mTOR activity and presumably Rhes acts as a modulator of 
mTOR via Akt signaling.  On the contrary one report has found that mTORC1 activation 
in HD striata promotes autophagy (Lee et al., 2015).   However; evidence shows that 
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Rhes stimulates autophagy through a completely different mTOR-independent pathway 
that involves relieving the inhibition of Beclin-1 which itself is a potent stimulator of 
mTOR independent autophagy (Kang, Zeh, Lotze, & Tang, 2011; Mealer, Murray, 
Shahani, Subramaniam, & Snyder, 2014).   Taken together, the suggestion by all of 
these reports is that Rhes may play a neuroprotective role, at least when it comes to 
inducing autophagy.  Evidence from this study may help to answer the question of Rhes 
role in autophagy.  Given the fact that aggregates did not differ between genotypes, and 
even trended toward being more frequent in Rhes normal mice, it might be assumed 
that Rhes is in fact not substantially affecting autophagy at the level of the mHtt 
aggregate.   
 Other recent evidence has also been found to support Rhes’ role in neurotoxicity.  
It was shown that in a novel human embryonic stem cell model of HD loss of neurons 
was significantly decreased when Rhes was knocked down using RNAi (Lu & Palacino, 
2013).  Another study has found that Rhes complexes with mHtt and ACBD3, a 
scaffolding protein responsible for regulation of neurotoxicity (Sbodio, Paul, Machamer, 
& Snyder, 2013).  Expression of Rhes with mHtt and ACBD3 in cultures resulted in a 
much higher cytotoxicity than expression of mHtt and ACBD3 together (Sbodio et al., 
2013).    Another study has found that Rhes expression in mHtt expressing cells results 
in a loss of mitochondrial potential leading to increased oxidative stress (Fabio, 2014).   
 All of this new evidence does not make it very easy to paint a uniform picture of 
Rhes’ involvement in HD.  On one hand we have an overwhelming line of evidence both 
in vivo and in vitro, suggesting that Rhes plays a neurotoxic role in the pathogensis of 
Huntington’s disease.  On the other hand we have some evidence that Rhes actually 
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plays a neuroprotective role in Huntington’s disease.  Evidence from the current study 
would suggest that Rhes deletion does not diminish the effect of mHtt aggregation on 
striatal neurons.  This is in contrast to the evidence suggesting that Rhes deletion 
should in fact cause an increase in aggregation.   
 One explanation for the results of this study may be that the methods used were 
not sensitive enough to properly distinguish a difference in aggregation between the 
genotypes.  Rhes may indeed be promoting early onset of aggregation but the temporal 
spacing used to detect this was not close enough.  The R6/1 mouse model of HD shows 
a relatively aggressive phenotype compared to other murine models of HD.  BacHD 
mice, for example, containing a full length human HD gene display a much less 
aggressive and a much longer temporal phenotype.  The methods used to stain and 
detect aggregates in this study would be more sensitive in a model with a longer 
temporal onset of aggregation.  It could be that the critical times of aggregation 
difference in the R6/1 model are in between 4 and 6 months whereas in models such as 
BacHD the window of aggregation difference is 8-16 months.  This also makes the 
important assumption that deletion of Rhes does not preclude the eventual cellular 
dysfunction and cell death, which is based on the previous evidence that Rhes deleted 
models of HD do eventually show a disease like phenotype but at a slower rate than 
Rhes normal mice.    
 Another possibility is that the R6/1 model changes aggregation behavior itself.  A 
recent study has found evidence that SUMO shows a higher binding affinity for mHtt 
based on the length of the polyQ sequence (Bhat, Yan, Wang, Li, & Xio-Jiang, 2014).  
Interestingly the group found that ubiquitin serine residue K63 preferentially binds the n-
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terminal of the expanded polyQ regions which promotes aggregation (Bhat et al., 2014).   
The suggestion is that there is a difference in the steric properties of the protein such 
that as the expanded polyQ changes in length, availability of the binding site for 
SUMO/Ubiquitin changes.  The R6/1 model contains a 116Q repeat length HD 
transgene (Mangiarini et al., 1996).  It is not out of the question that differential 
expression of repeat length size, size of expressed protein, or even different cleavage 
products based on either of these would result in differential effector protein interactions 
with mHtt.  A follow up study that stains for co-localization of mHtt with either ubiquitin or 
SUMO could help to answer this question.    
 Another interesting explanation may lie with the nature of SUMO itself.  SUMO 
exists in the 4 isoforms; SUMO-1, SUMO-2, SUMO-3, and SUMO-4 (O’Rourke et al., 
2013; Saitoh & Hinchey, 2000).  In a recent report it was shown that SUMO-1 and 
SUMO-2 differentially bind mHtt (O’Rourke et al., 2013).  Most notably the study found 
that SUMO-1 modification of mHtt resulted in more soluble fragmentation whereas 
SUMO-2 modification resulted in less solubility and more aggregation (O’Rourke et al., 
2013).  Interestingly the authors also found that SUMO-2 binding to mHtt was not 
associated with Rhes whereas, as previously reported, SUMO-1 binding to mHtt was 
enhanced by Rhes (O’Rourke et al., 2013). This interesting result fits perfectly with the 
observed results from the current study.  This suggests that Rhes deletion would 
downregulate the soluble fraction of toxic mHtt fragments via inability to act as an E3 
ligase for SUMO-1.  At the same time aggregation behavior would not be affected by 
Rhes as it does not promote SUMO-2 association with mHtt.   
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Conclusion 
 Rhes deletion does not significantly alter the aggregation of mHtt in a mouse 
model of Huntington’s disease, but it does significantly reduce the phenotypic symptoms 
of the disease.  Many important questions remain.  Why does Rhes deletion not effect 
aggregation despite the overwhelming evidence that it should? As Subramaniam and 
colleagues (2009) pointed out in their first publication on the subject, some models of 
HD show a high correlation with aggregation and cell death and some do not.  Model 
biochemical differences and methodologies used to study HD pathology perhaps 
underlie this discrepancy in the literature.  Another important underpinning in regards to 
Rhes’ contribution could lie in its ability to act as both a trophic entity and a neurotoxic 
species.  Evidence is beginning to support the idea that Rhes presence is important as 
a positive regulator of autophagy and a negative regulator of proteolysis.  Hypothetically 
Rhes involvement in a temporal fashion in proteolysis versus autophagy may help to 
explain why disease onset is later in life.  Regardless, this is the first study of its kind to 
look at aggregation behavior as it relates to Rhes in an in vivo model of HD, and as a 
result careful follow up should be considered.  
Future Studies 
 Rhes’ role in Huntington’s disease is an important avenue of research that should 
continue to be looked at very carefully.  Following up on the findings in this particular 
study could shed important light on not only the functions of Rhes, but on how 
progressive neuropathological disorders work in general.   One particularly interesting 
question is why did Rhes deletion not affect aggregation as expected?  Studies using 
different models of HD may be considered to address the limitation of a short 
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neuropathological time course.  A similar study using BacHD mice, which expresses the 
full HD transgene, and shows a much longer neuropathological and neurobehavioral 
phenotype, may be more sensitive for studying aggregate formation.  Another 
consideration would be the possibility of using similar methodology but incorporating 
fluorescent-tagged secondary antibodies as well as staining for ubiquitin and SUMO in 
addition to mHtt.  This would provide a much clearer picture of how these highly 
important regulators of HD neuropathology behave in relation to the formation of 
aggregates.   Ultrastructural analysis of MSNs using electron microscopy techniques 
should also be performed on Rhes-/-/HD+ mice.  Aggregate formation could differ from 
expected wild type mice at the level of the soma that is not visible using light 
microscopy techniques.  It would be interesting if the deletion of Rhes changes the 
quality of the aggregate on a structural or location level inside of the cell.   
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Institutional Animal Care and Use Committee 
U N I V E R S I T Y  O F  N E W  O R L E A N S  
 
 
 
DATE: November 17, 2012  
 
TO:  Dr. Gerald LaHoste 
 
FROM: Dr. Steven G. Johnson 
   Chairperson 
 
RE:  IACUC Protocol # UNO-12-007 
Entitled:  Rhes and Huntington’s Disease: Genetic Studies 
 
Your application for the use of animals in research (referenced above) has been approved 
beginning November 17, 2012 and expiring November 16, 2015.  We are concerned about the 
use of personal funds to conduct such experiments and would like to see a major progress report 
at the end of the first year.  To minimize the use of excess animals, we also need to see that 
scientific progress such as grants and publication is evident, especially given the dynamic nature 
of this area.  We will require this at the end of the first year and make a determination about 
whether approval is given to extend the protocol beyond the first year. Please note that a final 
report must be provided to the UNO IACUC.   
 
The University of New Orleans has an Animal Welfare Assurance on file with the Office of 
Laboratory Animal Welfare (OLAW), National Institutes of Health.  The assurance number is 
A3299-01. 
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